Preston Hollow Psychiatry Group

06/14/2024

On Wednesday, June 12, Dr. Bennett was joined by Grace, a real patient with treatment-resistant depression, at the Pri-Med conference in Irving, TX. Together they spoke to an audience of Primary Care Physicians to educate them about the role Spravato plays in difficult to treat depression and the impact this new medication can have on patients’ lives.
Follow the link to hear Grace’s story for yourself.

Spravato.com/spravato-patient-stories/

01/17/2024

Dallas Center for Advanced Depression Treatments, a vital part of Preston Hollow Psychiatry Group, is a Spravato® national training center

Dallas CADT was one of the first centers in the United States to offer FDA-approved Spravato. Due to the experience and success of Dr. Bennett's efforts, our center was chosen by Janssen Neuroscience to be one of only four Spravato national training centers in the country, and the only one in Texas. Part of Janssen's Academy for Treatment, Observation and Management (ATOM), the center trains physicians from all over the United States on the best practices needed to safely and optimally use Spravato in their own offices. The center takes great pride in being able to help patients in DFW as well as those beyond our local reach.

Preston Hollow Psychiatry Group is led by Dr. Marty N Bennett, a board certified psychiatrist. The group is a leader in cutting edge psychiatric treatment. The first and most experienced practice in the DFW offering Spravato treatment for Depression.

12/12/2023

Dr. Marty N. Bennett Named
D Magazine Best Doctor 2023

Each year, D Magazine recognizes DFW's best physicians as chosen by their peers. A board-certified Dallas psychiatrist for over 20 years, Dr. Bennett has pioneered breakthrough psychiatric care for patients suffering from severe mental health conditions.

07/04/2023

Preston Hollow Psychiatry Group is pleased to announce evening appointments are now available Monday-Thursday.
These appointments are for established patients who need more flexible appointment options.

03/31/2023

SPRAVATO® is a unique therapeutic option for patients with MDD who have had an inadequate response to 2 or more antidepressants (TRD). Even after multiple therapeutic approaches, patients with TRD may continue to experience symptoms of MDD. SPRAVATO® is the first NMDA receptor antagonist approved ...